Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (51-60 of 246) with videos related to

Pageof 25
Sort By:
International Journal of Clinical Pharmacology and Therapeutics|July 9, 2015
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration studyDaniela Baldoni, Shirin Bruderer, Naguib Muhsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 25, 2016
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjectsDominik Lott, Andreas Krause, Jasper Dingemanse, et al.
Hepatology (Baltimore, Md.)|September 22, 2007
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndromeFlorence Wong, Kevin Moore, Jasper Dingemanse, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 23, 2017
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist SelexipagMargaux Boehler, Shirin Bruderer, Ivan Ulč, et al.
Expert Opinion on Drug Safety|May 13, 2017
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertensionShirin Bruderer, Noémie Hurst, Tatiana Remenova, et al.
Immunopharmacology and Immunotoxicology|December 19, 2014
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulationsDaniele D'Ambrosio, Jörg Steinmann, Patrick Brossard, et al.
Epilepsia|April 21, 2019
First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blockerMuriel Richard, Priska Kaufmann, Rüdiger Kornberger, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 16, 2014
Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulatorAndreas Krause, Patrick Brossard, Daniele D'Ambrosio, et al.
Journal of Clinical Pharmacology|October 8, 2010
Influence of severe renal impairment on the pharmacokinetics of clazosentanShirin Bruderer, Boris Sasu, Nahum Tsvitbaum, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Influence of different degrees of liver impairment on the pharmacokinetics of clazosentanShirin Bruderer, Victor Detishin, Nahum Tsvitbaum, et al.
Pageof 25

Showing results (51-60 of 246) with videos related to

Sort By:
Pageof 25
International Journal of Clinical Pharmacology and Therapeutics|July 9, 2015
Bioequivalence of different dose-strength tablets of selexipag, a selective prostacyclin receptor agonist, in a multiple-dose up-titration studyDaniela Baldoni, Shirin Bruderer, Naguib Muhsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|April 25, 2016
Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjectsDominik Lott, Andreas Krause, Jasper Dingemanse, et al.
Hepatology (Baltimore, Md.)|September 22, 2007
Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndromeFlorence Wong, Kevin Moore, Jasper Dingemanse, et al.
European Journal of Drug Metabolism and Pharmacokinetics|June 23, 2017
Biocomparison Study of Adult and Paediatric Dose Strengths of the Prostacyclin Receptor Agonist SelexipagMargaux Boehler, Shirin Bruderer, Ivan Ulč, et al.
Expert Opinion on Drug Safety|May 13, 2017
Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertensionShirin Bruderer, Noémie Hurst, Tatiana Remenova, et al.
Immunopharmacology and Immunotoxicology|December 19, 2014
Differential effects of ponesimod, a selective S1P1 receptor modulator, on blood-circulating human T cell subpopulationsDaniele D'Ambrosio, Jörg Steinmann, Patrick Brossard, et al.
Epilepsia|April 21, 2019
First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blockerMuriel Richard, Priska Kaufmann, Rüdiger Kornberger, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 16, 2014
Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulatorAndreas Krause, Patrick Brossard, Daniele D'Ambrosio, et al.
Journal of Clinical Pharmacology|October 8, 2010
Influence of severe renal impairment on the pharmacokinetics of clazosentanShirin Bruderer, Boris Sasu, Nahum Tsvitbaum, et al.
British Journal of Clinical Pharmacology|December 15, 2010
Influence of different degrees of liver impairment on the pharmacokinetics of clazosentanShirin Bruderer, Victor Detishin, Nahum Tsvitbaum, et al.
Pageof 25